Implantable technology for long-term delivery of nalmefene for treatment of alcoholism

International Journal of Pharmaceutics

Volumn 283, Issue 1-2, 2004, Pages 35-44

  Costantini, Lauren C ^a   Kleppner, Sofie R ^a   McDonough, Joseph ^b   Azar, Marc R ^c,d   Patel, Raj ^a  

^a Titan Pharmaceuticals Inc   (United States)

^b SOUTHWEST RESEARCH INSTITUTE   (United States)

^c San Diego Laboratories Inc   (United States)

^d Behavioral Pharma Inc   (United States)

Author keywords

Alcohol dependence; Alcoholism; Ethylene vinyl acetate; Long term delivery; Nalmefene

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; NALMEFENE; OPIATE ANTAGONIST;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPLANTATION; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ALCOHOLISM; ANIMALS; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; EQUIPMENT DESIGN; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; TECHNOLOGY, PHARMACEUTICAL;

EID: 4444279257     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.05.034     Document Type: Article

References (32)

1. F. Bibbiani, L.C. Costantini, R.A. Patel, and T.N. Chase Continuous apomorphine administration with novel EVA implants reduces the risk of motor complications compared to pulsatile apomorphine in l-DOPA-NAVE, MPTP-lesioned primates Am. Acad. Neurol. 2003
2. F. Bibbiani, J.D. Oh, L.C. Costantini, R. Patel, and T.N. Chase Continuous dopaminergic stimulation reduces the risk of motor complication in animal models of Parkinson's disease Soc. Neurosci. 2003
3. B.L. Chow, E.M. Sellers, and D.M. Tomkins Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats Behav. Pharmacol. 8 1997 725 735
4. G. Corrao, V. Bagnardi, A. Zambon, S. Arico, C. Dall'Aglio, G. Addolorato, and I. Giorgi Outcome variables in the evaluation of alcoholics' treatment: lessons from the Italian assessment of alcoholism treatment (ASSALT) project Alcohol Alcohol. 34 1999 873 881
5. R.S. Croop, E.B. Faulkner, and D.F. Labriola The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study Arch. Gen. Psychiatry 54 1997 1130 1135 The Naltrexone Usage Study group
6. R. Dixon, J. Gentile, H.B. Hsu, J. Hsiao, J. Howes, D. Garg, and D. Weidler Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist J. Clin. Pharmacol. 27 1987 233 239
7. R. Dixon, J. Howes, J. Gentile, H.B. Hsu, J. Hsiao, D. Garg, D. Weidler, M. Meyer, and R. Tuttle Nalmefene: intravenous safety and kinetics of a new opioid antagonist Clin. Pharmacol. Ther. 39 1986 49 53
8. D.J. Drobes, R.F. Anton, S.E. Thomas, and K. Voronin A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene Neuropsychopharmacology 28 2003 755 764
9. P.J. Fudala, S.J. Heishman, J.E. Henningfield, and R.E. Johnson Human pharmacology and abuse potential of nalmefene Clin. Pharmacol. Ther. 49 1991 300 306
10. R.K. Fuller, L. Branchey, D.R. Brightwell, R.M. Derman, C.D. Emrick, F.L. Iber, K.E. James, R.B. Lacoursiere, K.K. Lee, and I. Lowenstam Disulfiram treatment of alcoholism. A veterans administration cooperative study JAMA 256 1986 1449 1455
11. B.F. Grant, T.C. Harford, D.A. Dawson, P. Chou, M. DuFour, and R. Pickering Prevalence of DSM-IV alcohol abuse and dependence Alcohol Health Res. World 18 1994 243 248
12. R.J. Hamilton, R.E. Olmedo, S. Shah, O.L. Hung, M.A. Howland, J. Perrone, L.S. Nelson, N.L. Lewin, and R.S. Hoffman Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets Acad. Emerg. Med. 9 2002 63 68
13. C.L. Hubbell, S.H. Marglin, S.J. Spitalnic, M.L. Abelson, K.D. Wild, and L.D. Reid Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage Alcohol 8 1991 355 367
14. J. Johnsen, and J. Morland Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome Alcohol Clin. Exp. Res. 15 1991 532 536
15. J. Johnsen, A. Stowell, J.E. Bache-Wiig, T. Stensrud, A. Ripel, and J. Morland A double-blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation Br. J. Addict. 82 1987 607 613
16. H.L. June, C. Grey, C. Warren-Reese, L.F. Durr, A. Ricks-Cord, A. Johnson, S. McCane, L.S. Williams, D. Mason, R. Cummings, and A. Lawrence The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats Alcohol Clin. Exp. Res. 22 1998 2174 2185
17. J.H. Krystal, J.A. Cramer, W.F. Krol, G.F. Kirk, and R.A. Rosenheck Naltrexone in the treatment of alcohol dependence N. Engl. J. Med. 345 2001 1734 1739
18. B.J. Mason, E.C. Ritvo, R.O. Morgan, F.R. Salvato, G. Goldberg, B. Welch, and E. Mantero-Atienza A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence Alcohol Clin. Exp. Res. 18 1994 1162 1167
19. B.J. Mason, F.R. Salvato, L.D. Williams, E.C. Ritvo, and R.B. Cutler A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence Arch. Gen. Psychiatry 56 1999 719 724
20. M.E. Michel, G. Bolger, and B.A. Weissman Binding of a new opiate antagonist, nalmefene, to rat brain membranes Methods Find. Exp. Clin. Pharmacol. 7 1985 175 177
21. A.L. Misra, and R.B. Pontani An improved long-acting delivery system for narcotic antagonists NIDA Res. Monogr. 28 1981 254 264
22. S.S. O'Malley, A.J. Jaffe, G. Chang, R.S. Schottenfeld, R.E. Meyer, and B. Rounsaville Naltrexone and coping skills therapy for alcohol dependence. A controlled study Arch. Gen. Psychiatry 49 1992 881 887
23. Patel, R.A., Costantini, L.C., Hale, V., Jacobs, A., 2002. Long term delivery of buprenorphine by an implantable delivery system. In: Proceedings of the International Conference on Pain and Drug Dependency.
24. A.D. Schwope, D.L. Wise, and J.F. Howes Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction Natl. Inst. Drug Abuse Res. Monogr. Ser. 1975 13 18
25. B. Tabakoff, and P.L. Hoffman Alcohol interactions with brain opiate receptors Life Sci. 32 1983 197 204
26. J.R. Volpicelli, A.I. Alterman, M. Hayashida, and C.P. O'Brien Naltrexone in the treatment of alcohol dependence Arch. Gen. Psychiatry 49 1992 876 880
27. White, J., 2003. Probuphine™ for the Treatment of Opiate Addiction - Preliminary Results. International Society of Addiction Medicine.
28. C.R. Whyte, and P.M. O'Brien Disulfiram implant: a controlled trial Br. J. Psychiatry 124 1974 42 44
29. A. Wilson, W.J. Davidson, and R. Blanchard Disulfiram implantation: a trial using placebo implants and two types of controls J. Stud. Alcohol. 41 1980 429 436
30. A. Wilson, W.J. Davidson, R. Blanchard, and J. White Disulfiram implantation: a placebo-controlled trial with two-year follow-up J. Stud. Alcohol. 39 1978 809 819
31. A. Wilson, W.J. Davidson, and J. White Disulfiram implantation: placebo, psychological deterrent, and pharmacological deterrent effects Br. J. Psychiatry 129 1976 277 280
32. B.C. Yoburn, A.H. Cohen, and C.E. Inturrisi Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat J. Pharmacol. Exp. Ther. 237 1986